Anaphylactic Reaction to Carboplatin Diagnosed by Skin Testing-a reliable Tool in Platinum-based Immediate-type Hypersensitivity Reactions

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2022 May 20

PMID 35595936

Authors

Elias Marquart

Ahmad Jalili

Nadine Mothes-Luksch

Stephan N Wagner

Tamar Kinaciyan

Affiliations

Soon will be listed here.

Abstract

Immediate-type hypersensitivity reactions (IHRs) to carboplatin (CA) are most commonly reported in ovarian cancer patients. A 54-year-old woman with stage IV melanoma suffering from metastasis in the entire right lower extremity was presented to our allergy outpatient clinic for diagnostic work-up due to an anaphylactic reaction with palmoplantar erythema, conjunctivitis along with facial erythema, and an incipient decrease in blood pressure during a chemotherapy regimen with dacarbazine and carboplatin upon re-administration. A subsequently carried out allergological work-up with skin testing (ST) revealed CA to be the culprit drug, whereas cisplatin (CI) was confirmed to be a safe alternative for the patient for following treatments. Here, we report a case of an IHR to carboplatin in a melanoma patient, with CI serving as a safe alternative diagnosed by skin testing.

Citing Articles

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data.

Li K, Yin R Front Immunol. 2024; 15:1346464.

PMID: 38312839 PMC: 10834667. DOI: 10.3389/fimmu.2024.1346464.

References

Lax T, Long A, Banerji A . Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions. J Allergy Clin Immunol Pract. 2015; 3(6):856-62. DOI: 10.1016/j.jaip.2015.07.003. View

Scherer K, Brockow K, Aberer W, Gooi J, Demoly P, Romano A . Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013; 68(7):844-52. DOI: 10.1111/all.12161. View

Rose P, Fusco N, Smrekar M, Mossbruger K, Rodriguez M . Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003; 89(3):429-33. DOI: 10.1016/s0090-8258(03)00178-1. View

Pasteur J, Favier L, Pernot C, Guerriaud M, Bernigaud C, Lepage C . Low Cross-Reactivity Between Cisplatin and Other Platinum Salts. J Allergy Clin Immunol Pract. 2019; 7(6):1894-1900. DOI: 10.1016/j.jaip.2019.01.057. View

Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif M . Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010; 2010. PMC: 2945654. DOI: 10.1155/2010/207084. View

Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R . Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2017; 144(1):72-76. DOI: 10.1016/j.ygyno.2016.10.023. View

Cernadas J, Vasconcelos M, Fernandes A, Carneiro-Leao L, Gil-da-Costa M . Desensitization to carboplatin in low-grade glioma. A revision of 100 treatments in children. Pediatr Allergy Immunol. 2021; 32(6):1388-1391. DOI: 10.1111/pai.13525. View

Brockow K, Garvey L, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo M . Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013; 68(6):702-12. DOI: 10.1111/all.12142. View

Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L . Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?. Anticancer Drugs. 2009; 21(3):333-8. DOI: 10.1097/CAD.0b013e32833418c0. View

10.

Tai Y, Tai Y, Hsu H, Lee S, Chen Y, Chiang Y . Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Front Pharmacol. 2017; 8:800. PMC: 5681487. DOI: 10.3389/fphar.2017.00800. View

11.

Legha S, Ring S, Bedikian A, Plager C, Eton O, Buzaid A . Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996; 7(8):827-35. DOI: 10.1093/oxfordjournals.annonc.a010762. View